Skip to main content

Table 1 Demographic, clinical, histological, metabolic features, and PNPLA3 I148M genotype of NAFLD and CHC patients, and healthy controls with very low probability of steatosis

From: The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

  NAFLD patients (n = 144) CHC patients (n = 261) Healthy controls (n = 257)
Sex (F) 32 (22%) 110^ (42%) 55 (21%)
Age (years) 49.5±12 58.1±14^ 48±12
BMI (Kg/m2) 26.8±3.3^ 25.4±3.9 25.0±2.8
Ferritin (ng/ml) 470±420^ 248±372^ 52±47
Total cholesterol (mg/dl) 206±40 178±38^ 193±33
HDL cholesterol (mg/dl) 47±13^ 50±17^ 57±13
Triglycerides (mg/dl) 133±64^ 105±50^ 88±46
Glucose (mg/dl) 98±27^ 95±23^ 67±39
Diabetes 17 (12%)^ 47 (18%)^ 0
ALT (IU/ml) 60±46^ 70±59^ 22±9
GGT (IU/ml) 87±122^ 61±69^ 21±13
Steatosis 144 (100)^ 179 (69)^ 0
Steatosis 2-3 41* (36)^ 23 (9)^ 0
NASH 52* (45) NA NA
Fibrosis 60* (52) 258 (99) NA
Cirrhosis 0 80 (31)^ 0
FFAs (mmol/l)° 0.22 ± 0.01^ NA 0.16±0.01
Insulin (IU/ml)° 14.3 {10.8-20}^ NA 11.7 {9.2-14.5}^
HOMA-IR° 3.2 {2.5-4.8}^ NA 2.5 {1.9-3.2}
Adipo-IR° 14.9±14.5^ NA 6.1±2.7
Adiponectin (μg/ml) 4.9 {3.0-7.8}^ 9.4 {5.7-13.3}^ 6.6 {4.7-9.3}
ADIPOQ    
rs2241766TT and rs1501299T+ 83 (57) 143 (55) 142 (55)
rs2241766G + or rs1501299GG 61 (43) 118 (45) 115 (45)
PNPLA3 rs738409    
CC (148 I/I) 55 (38) 133 (51) 146 (57)
CG (148 I/M) 68 (47) 103 (39) 95 (37)
GG (148 M/M) 21 (15) 25 (10) 16 (6)
  1. BMI body mass index, HOMA-IR homeostasis model assessment insulin resistance index, NASH nonalcoholic steatohepatitis, FFAs free fatty acids, Adipo-IR adipose tissue insulin resistance index, NA not addressed, ():% values, *n = 115 patients with liver biopsy, adiponectin (ADIPOQ) genotype was classified according to [29], available in all patients and 68 healthy controls, ^p < 0.05 vs. controls.